The Market
The Opioid Analgesic Market is Over $10 Billion in the US
- Hydrocodone is the most prescribed opioid analgesic, as well as the most prescribed drug in the US - peaking at 137 million prescriptions in 2013
- Immediate release products for acute pain indications account for 90% of opioid prescriptions written, while extended release products for chronic pain account for the remaining 10%
- Quivive's first product (QEV-817) is an immediate release combination of Hydrocodone and Doxapram for acute pain indications
- FDA may withdraw all prescription opioids that do not feature abuse deterrence - opening the market for new and safer alternatives
The Competition
An Unmatched Combination of Improved Safety and Abuse Deterrence
- New analgesics have unknown side effect profiles and are not therapeutically equivalent to existing products - leading to slow uptake by physicians
- Abuse-deterrent reformulations of existing opioids do NOT limit oral over-consumption – the most common form of abuse of Rx opioids
- Quivive's product (QEV-817) will offer a unique safety benefit by limiting respiratory depression in case of accidental or intentional overdose
- QEV-817 will be therapeutically equivalent to existing hydrocodone products - supporting Tier 1 formulary status and rapid uptake by physicians
The Intellectual Property
Quivive's Strong IP Position will Support a Platform of Future Products
- Quivive has broad US-PTO and WO-PCT applications covering the combination of any opioid with any respiratory stimulant
- Our first patent (US-PTO No. 10,004,479) was granted in 2018 for the oral combination of Hydrocodone and Doxapram
- Future patents will cover a broad range of combinations, supporting a future pipeline of safer and abuse deterrent opioid analgesic products